Eunkyung Park, M.D. Ph.D.
Korean J Hematol 2011; 46(3): 145-147Takefumi Matsushita, Ph.D.
Korean J Hematol 2011; 46(3): 148-150Seung-Ah Yahng, and Hee-Je Kim
Korean J Hematol 2011; 46(3): 151Sung Ran Cho, M.D. Ph.D.
Korean J Hematol 2011; 46(3): 152Paul J. Martin, Yoshihiro Inamoto, Paul A. Carpenter, Stephanie J. Lee, and Mary E.D. Flowers
Korean J Hematol 2011; 46(3): 153-163Mario Schiffer, and Jan T. Kielstein
Korean J Hematol 2011; 46(3): 164-168Dong-Wook Kim
Korean J Hematol 2011; 46(3): 169-174Jin Seok Kim, Soo-Jeong Kim, June-Won Cheong, Yundeok Kim, Doh Yu Hwang, Sulhee Yoon, Jieun Jang, Shin Young Hyun, and Yoo Hong Min
Korean J Hematol 2011; 46(3): 175-179Jae-Sook Ahn, Deok-Hwan Yang, Sung-Hoon Jung, Soo-Young Bae, Huong Thi Thanh Tran, Hyung Chul Park, Ha-Na Kim, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, and Je-Jung Lee
Korean J Hematol 2011; 46(3): 180-185Won-ik Choi, You Cheol Jeong, Sun Young Kim, So Dam Kim, John Paul Pribis, Hee-Jin Kim, Kyung-Nam Koh, Ho-Joon Im, Young-Ho Lee, and Jong-Jin Seo
Korean J Hematol 2011; 46(3): 186-191
The clinical score distribution at initial diagnosis. Scores between 1 and 2 were assigned to 75.9% (N=101) of cases, between 3 and 6 to 15.8% (N=21), and more than 6 to 8.3% (N=11). The number of patients with a score of 1 or 2 was significantly higher than the other groups.
|@|~(^,^)~|@|The age distribution of 3 clinical score categories. In the group with scores of 1 or 2, the number of patients who were less than 2 years of age was higher than in the group with scores higher than 3. However, this difference did not reach statistical significance.
|@|~(^,^)~|@|The curve of reactivation free survival rate. The reactivation-free survival curves during follow-up in the high score group (>6) was significantly lower than in groups with lower scores.